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Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian
cancer (EOC). This was investigated in the current analysis.
Methods:We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS),
progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC
patients with and without previous BC.
Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard
ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03–2.08 and HRmult 1.43; 95% CI 1.01–2.03), and a non-significantly worse OS
(HRmult 1.15; 95% CI 0.84–1.57) and OCSS (HRmult 1.18; 95% CI 0.85–1.62). Ovarian cancer-specific survival was significantly worse
for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21–3.31).
Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC
patients without BC, especially when treated with adjuvant chemotherapy.
It is assumed that 8–16% of all epithelial ovarian cancer (EOC)
cases are due to BRCA1/2 germ line mutations (Risch et al, 2001;
Thompson et al, 2002; Alsop et al, 2012). An improved survival
after primary therapy has been reported for BRCA1/2-associated
compared with sporadic EOC patients (Vencken et al, 2011;
Yang et al, 2011; Hyman et al, 2012). This is thought to be
explained by the crucial role of BRCA genes in homologous
recombination, a mechanism to repair double-strand DNA breaks,
which is deficient in patients without functional BRCA proteins.
Platinum chemotherapy, like cisplatin or carboplatin, being a
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cornerstone in EOC treatment, typically induces double-strand
DNA breaks leading to more cancer cell death in BRCA1/2
mutation carriers.
Around 30–50% of the BRCA1/2-associated EOC patients have
been treated for previous breast cancer (BC; Alsop et al, 2012;
Vencken et al, 2013), whereas data on the incidence of EOC after
Table 1. Patient, tumour and treatment characteristics of OC in BRCA1/2 patients with and without a history of BC
Patients with a history of BC
N %
Patients without a history of BC
N % P-value
Total number of patients 116 30 270 70
Age at diagnosis 0.09
Median in years (range) 53.1 (39.0–77.1) 52.0 (23.2–89.7)
Mean in years (s.d.) 54.3 (8.3) 52.6 (9.1)
Follow-up time 0.15
Median in years (range) 4.9 (0.4–33.4) 5.6 (0.1–33.1)
Type of mutation 0.18
BRCA1 89 77 188 70
BRCA2 27 23 82 30
BRCA1/2 testing after EOC diagnosisa 71 64 211 82 o0.001
Mean time after EOC in years 3.6 4.3 0.28
Median time after EOC in years 1.4 2.2
Year of diagnosis 0.16
1980–1989 9 8 32 12
1990–1999 35 30 83 31
2000–2009 60 52 142 53
X2010 12 10 13 5
CA-125 (kU l-1) at primary diagnosis 0.02
o35 19 16 20 7
35–500 28 24 81 30
4500 31 27 94 35
Unknown 38 33 75 28
Histology 0.77
Serous 75 65 166 62
Mucinous 5 4 8 3
Endometrioid 8 7 28 10
Clear cell 0 0 3 1
Undifferentiated 7 6 18 7
Adenocarcinoma NOS 16 14 34 13
Other 1 1 6 2
Unknown 4 3 7 3
Tumour grade (Silverberg) 0.99
1 (well differentiated) 5 4 11 4
2 (moderately differentiated) 24 21 55 20
3 (poorly differentiated) 72 62 172 64
Unknown 15 13 32 12
FIGO stage 0.56
I 17 15 29 11
II 15 13 35 13
III 57 49 153 57
IV 23 20 48 18
Unknown 4 3 5 2
Surgery 0.71
Primary surgery 81 70 172 64
Interval debulking 9 8 24 9
Both 24 21 70 26
None 0 0 1 0
Unknown 2 2 3 1
Radiotherapy 0.79
Yes 5 4 10 4
No 103 89 236 87
Unknown 8 7 24 9
Chemotherapy 0.68
Platinum with Paclitaxel 77 66 182 67
Platinum without Paclitaxel 30 26 72 27
Other 3 3 2 1
No 6 5 11 4
Unknown 0 0 3 1
Duration of chemotherapy for primary OC 0.07
Median in weeks (range) 18.7 (1.3–47.7) 20.0 (2.1–98.6)
Mean in weeks (s.d.) 20.5 (7.9) 22.7 (11.8)
Abbreviations: BC¼breast cancer; FIGO¼ international federation of gynecology and obstetrics; OC¼ovarian cancer; NOS¼ not otherwise specified.
aDate of DNA test was missing for 18 patients (5 with and 13 without a BC history).
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BC in BRCA1/2 mutation carriers are scarce. Metcalfe reported a
10-year actuarial risk of developing EOC after BC of 12.7% for
BRCA1 and of 6.8% for BRCA2 mutation carriers (P¼ 0.03)
(Metcalfe et al, 2005). Currently it is unknown whether a BC
history affects the outcome of subsequent EOC in BRCA1/2
mutation carriers, especially as treatment for early BRCA-
associated BC frequently includes adjuvant chemotherapy.
In the current study we evaluated the outcome of EOC in
BRCA1/2 mutation carriers with and without a BC history. In
addition, we investigated the impact of adjuvant chemotherapy for
BC on the outcome of BRCA1/2-associated EOC.
MATERIALS AND METHODS
Patients. Initially, we selected EOC patients identified with a
BRCA1 or BRCA2 mutation, diagnosed between 1980 and 2008
from databases at all eight Dutch University Medical Centres, one
Cancer Centre and the Netherlands Foundation for the Detection
of Hereditary Tumours (STOET), as has been described previously
(Vencken et al, 2013). In four centres both BRCA1 and BRCA2
patients were included, whereas in six centres, due to a lower
prevalence, only BRCA2 patients were included. In addition, from
the Erasmus MC in Rotterdam BRCA1/2-associated EOC patients
treated between 2008 and 2015 were included. Exclusion criteria
were a previous malignancy (except for BC and basal cell
carcinoma), a borderline ovarian tumour and a primary or
recurrent BC synchronous with EOC.
For the selected patients, data concerning tumour character-
istics, treatment for BC and EOC, and follow-up were collected
from medical records. The medical ethical committee of the
Erasmus MC, Rotterdam (MEC-2014–429) approved the study.
Definitions. The main outcome measures were progression-free
survival (PFS), progression-free interval (PFI), overall survival (OS)
and ovarian cancer-specific survival (OCSS).
Progression-free survival was defined as the time between the
date of EOC diagnosis and the date of progressive or recurrent
disease. Progression-free interval was defined as the time between
the last day of first-line treatment for EOC and the date of
progressive/recurrent disease. The end date of chemotherapy was
estimated if the last day of chemotherapy was unknown. Overall
survival was defined as the time between date of EOC diagnosis
and date of death. Ovarian cancer-specific survival was defined as
the time between the date of EOC diagnosis and the date of death
due to EOC.
Statistics. Differences in tumour and treatment characteristics
between EOC patients with and without a history of BC were tested
with the Pearson’s w2-test or, in case of small numbers, with the
Fisher’s exact test (categorical variables) or with the Student’s t-test
(continuous variables). Progression-free survival, PFI, OS and
OCSS were calculated using the Kaplan–Meier survival method for
patients with and without a previous BC separately. Subsequent
analyses were performed for the group of patients treated with and
without adjuvant chemotherapy for a previous BC separately. To
account for the time elapsed between EOC diagnosis and genetic
testing, we performed left-truncated survival analyses. Patients
were censored at date of loss to follow-up, or end date of the study
(April 2015). For PFS, PFI and OCSS patients were also censored at
date of death not due to EOC. Differences between the groups were
tested by means of a log rank test. Univariate as well as multivariate
Cox proportional hazard regression models were performed, to
calculate hazard ratio’s (HRs) and 95% confidence intervals (95%
CIs). Following confounding factors were included in the multi-
variate regression model: age at EOC diagnosis (continuous), year
of EOC diagnosis (o2000; X2000), CA-125 level at diagnosis
(o35; 35–500; 4500; unknown), differentiation grade
(grade I and grade II; grade III; unknown), FIGO stage
(I- IIa;4IIa; unknown), type of mutation (BRCA1; BRCA2) and
chemotherapy regimen for EOC (platinum/paclitaxel; platinum
without paclitaxel; non-platinum-based; unknown). Analyses were
performed using SPSS (version 21.0; SPSS, Inc., Chicago, IL, USA)
or Stata (version 14; Stat Corporation, College Station, TX, USA).
A two-sided P-valueo 0.05 was considered statistically significant.
RESULTS
Patient, tumour and treatment characteristics of 116 EOC patients
with previous BC and 270 without previous BC are presented in
Table 1. In Supplementary Table 1, data on BC treatment are
summarised. The median age at EOC diagnosis was 51.8 for
BRCA1 and 56.3 years for BRCA2 patients, and 73% of the patients
were diagnosed with advanced stage disease (X FIGO stage IIb).
CA-125 values at EOC diagnosis were lower in the group with
previous BC (P¼ 0.02). The patients with previous BC were less
often tested for BRCA1/2 mutations after their EOC diagnosis
(Po0.001). There were no other significant differences between
the characteristics of the two patient groups, with and without
previous BC, observed (Table 1).
Progression-free survival was not significantly different for
patients with previous BC compared with patients without a
previous BC (5-year PFS 22% vs 28%; Figure 1a and
Supplementary Table 2). In the multivariate analysis, however,
PFS was significantly lower in the group with previous BC
(HR multivariate (HRmult) 1.47; 95% CI 1.03–2.08). Similar data
were observed for PFI, at univariate analysis no significant
difference was found between the two patient groups, whereas in
the multivariate analysis the group with a history of BC had a
shorter PFI (HRmult 1.43; 95% CI 1.01–2.03; Figure 1b and
Supplementary Table 2). No significant difference was found
regarding OS (HRmult 1.15; 95% CI 0.84–1.57) and OCSS (HRmult
1.18; 95% CI 0.85–1.62) between patients with and without a
history of BC (Supplementary Table 2 and Figure 1c and d). The
time between BC diagnosis and EOC diagnosis was not associated
with PFS (HRmult 1.00; 95% CI 0.96–1.04), nor with OCSS (HRmult
0.99; 95% CI 0.95–1.04; data not shown).
To address the possible impact of adjuvant chemotherapy
administered for BC on the PFS and OCSS of subsequent EOC
patients with BC before OC treated with chemotherapy and
patients not treated with adjuvant chemotherapy for BC were
separately analysed and compared with EOC patients without
previous BC (Figure 2 and Supplementary Table 3). We observed
that PFS and OCSS were especially worse for patients treated with
adjuvant chemotherapy for previous BC vs patients without
previous BC (median 1.5 vs 2.0, and median 5.0 vs 5.3 years,
respectively). In the multivariate analyses these differences were
significant (HRmult 2.38; 95% CI 1.40–4.02 and HRmult 1.99; 95%
CI 1.21–3.31, respectively). The patients with a BC history not
treated with adjuvant chemotherapy had similar PFS and OCSS
compared with EOC patients without a BC history (HRmult 1.16;
95% CI 0.76–1.79 and HRmult 0.87; 95% CI 0.59–1.29, respectively;
Figure 2 and Supplementary Table 3).
DISCUSSION
In the current study, we observed a significantly worse PFS and
PFI, in BRCA-associated EOC patients with a BC history vs EOC
patients without a previous BC, not yet resulting in a significantly
worse survival. A significantly worse OCSS, however, was found in
BRCA-associated EOC patients treated with adjuvant chemother-
apy for BC compared with EOC patients without previous BC.
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No differences in grade, stage and histology were observed
between both groups. A first hypothetical explanation for this
survival difference might be that chemotherapy induces mutations
and alters the behaviour of already present malignant EOC cells, or
induces chromosomal instability in stem cells with subsequent
development of EOC. Another possible explanation might be that
treatment for the initial BC aggravates the (bone marrow)
condition of the patient and, therefore, optimal therapy for EOC
cannot be given to these patients. However, the time between
BC diagnosis and OC diagnosis was not associated with outcome,
suggesting that the condition of the patients is not the main reason
for the worse survival in patients with a BC history.
The retrospective nature of the study brings corresponding
limitations, such as different treatments regimens, and some
missing data. Another limitation includes that the majority
of the patients were tested for a BRCA1/2 mutation after
EOC diagnosis (64% and 82% in the groups with and
without a BC history, respectively), this will select for survivors.
To account for this possible survivorship bias we have conducted
left-truncation survival analyses. Because of the retrospective
design, no firm conclusions can be drawn and our results
should be confirmed in other (prospective) studies with greater
sample size.
The results of this study underline the importance of offering
genetic testing to BC patients being at risk of BRCA1/2 mutation
carriership. Newly diagnosed mutation carriers can then be
informed about risk reducing salpingo-oophorectomy, which has
been associated with improved survival (Finch et al, 2014). Further,
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Figure 1. Progression free survival (A), progression free interval (B), overall survival (C) and ovarian cancer-specific survival (D) for BRCA1/2
epithelial ovarian cancer patients with and without a BC history. BC, breast cancer; CI, confidence interval; HR, hazard ratio.
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we suggest that studies on survival in BRCA1/2-associated EOC
should stratify for BC history.
ACKNOWLEDGEMENTS
This study was supported by the Dutch Cancer Society (EMCR
2014–6699). We thank Petra Bos, Annemarie de Jong, Natalia
Teixeira, Fon Kosterman and Kelly Kesselaar for their assistance in
data collection.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, Dobrovic A,
Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G
(2012) BRCA mutation frequency and patterns of treatment response in
BRCA mutation-positive women with ovarian cancer: a report from the
Australian Ovarian Cancer Study Group. J Clin Oncol 30:
2654–2663.
Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, Rosen B,
Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD,
Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA,
Thompson I, Murphy J, Sun P, Narod SA (2014) Impact of oophorectomy
on cancer incidence and mortality in women with a BRCA1 or BRCA2
mutation. J Clin Oncol 32: 1547–1553.
Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF,
Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR,
Kauff ND (2012) Improved survival for BRCA2-associated serous ovarian
cancer compared with both BRCA-negative and BRCA1-associated serous
ovarian cancer. Cancer 118: 3703–3709.
Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD,
Warner E, Olopade O, Eisen A, Weber B, Mclennan J, Sun P, Narod SA
(2005) The risk of ovarian cancer after breast cancer in BRCA1 and
BRCA2 carriers. Gynecol Oncol 96: 222–226.
Risch HA, Mclaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E,
Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA
(2001) Prevalence and penetrance of germline BRCA1 and BRCA2
mutations in a population series of 649 women with ovarian cancer.
Am J Hum Genet 68: 700–710.
Thompson D, Easton DF, Breast Cancer Linkage, C. (2002) Cancer
Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:
1358–1365.
Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ,
Berns EM, Jager A, Collee M, Burger CW, Seynaeve C (2011)
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian
cancer patients after first-line chemotherapy compared with sporadic
ovarian cancer patients. Ann Oncol 22: 1346–1352.
Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA,
van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK,
van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW,
Seynaeve C (2013) Outcome of BRCA1- compared with BRCA2-
associated ovarian cancer: a nationwide study in The Netherlands.
Ann Oncol 24: 2036–2042.
Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W (2011)
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy
sensitivity, and gene mutator phenotype in patients with ovarian cancer.
JAMA 306: 1557–1565.
This work is licensed under the Creative Commons
Attribution-Non-Commercial-Share Alike 4.0 Inter-
national License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Outcome of OC after BC
1178 www.bjcancer.com |DOI:10.1038/bjc.2016.333
